Cinven buys women's health drugmaker Theramex in €2.6bn buyout

What's the deal? Private equity firm CinvenDealroom has a profile for this one. Try Dealroom → has agreed to acquire TheramexDealroom has a profile for this one. Try Dealroom →, a London-based specialty pharmaceutical company focused on women's health, from Carlyle and PAI PartnersDealroom has a profile for this one. Try Dealroom →, in a buyout worth about €2.6 billion — almost double the roughly €1.4 billion Carlyle and PAI paid for Theramex in 2022, according to the Financial Times. The deal is expected to close in the first half of 2027, subject to regulatory approval.

What does Theramex do? The company develops, licenses, and sells treatments across four areas: menopause, osteoporosis, contraception, and fertility. Its more than 500 employees serve patients in over 80 countries across Europe, Africa, Asia-Pacific, and Latin America, and its treatments have reached more than six million women.

Why now? The sale caps a strong run under Carlyle and PAI, which say they more than doubled Theramex's EBITDA since acquiring the business in 2022, expanding through product launches, licensing, and acquisitions.

What's the endgame? Cinven plans to deepen Theramex's footprint in existing markets, push into new geographies, and pursue in-licensing deals. "Theramex combines a market-leading position in women's health with a resilient commercial model and a clear, credible growth strategy," said Philipp Meyer, a partner in Cinven's healthcare team.

The deal builds on Cinven's healthcare track record, which includes STADADealroom has a profile for this one. Try Dealroom →, LGCDealroom has a profile for this one. Try Dealroom →, and SynlabDealroom has a profile for this one. Try Dealroom →. "Women's health is a large and growing area of healthcare that has historically been underserved," said Pontus Pettersson, head of Cinven's healthcare team.

The signal: The sponsor-to-sponsor deal lands amid renewed investor interest in women's health, following Blackstone and TPG's 2025 take-private of diagnostics company HologicDealroom has a profile for this one. Try Dealroom →. Theramex is a distinct specialty-pharma bet, signalling that private capital sees durable growth in a long-underserved market.

Read more: cinven.com · Financial Times

Image credit: Generated with Gemini